The Influence of Metabolic Factors for Nonalcoholic Fatty Liver Disease in Women

Table 5

Unadjusted and adjusted analyses for the risk of NAFLD in postmenopausal women.

	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
Age	1.03 (0.99–1.06)	0.124	0.97 (0.93–1.01)	0.179
Hypertension	2.68 (1.73–4.17)	<0.001	1.50 (0.86–2.61)	0.152
Diabetes	3.57 (2.22–5.74)	<0.001	2.38 (1.30–4.37)	0.005
Triglyceridemia	5.57 (3.09–10.03)	<0.001	4.51 (2.16–9.43)	<0.001
HDL	0.46 (0.29–0.75)	0.002	0.85 (0.46–1.57)	0.592
Central obesity	4.91 (3.10–7.76)	<0.001	4.17 (2.40–7.23)	<0.001
Hormone therapy	0.03 (0.13–0.88)	0.026	0.47 (0.15–1.44)	0.185
Smoking	0.78 (0.21–2.89)	0.713	0.56 (0.13–2.45)	0.439
Exercise	1.59 (0.96–2.62)	0.072	1.35 (0.74–2.48)	0.332
ALT	1.07 (1.04–1.10)	<0.001	1.07 (1.04–1.10)	<0.001
GGT	1.01 (1.00–1.02)	0.022	0.99 (0.98–1.00)	0.122
HOMA	1.72 (1.37–2.16)	<0.001	1.02 (0.84–1.24)	0.838

NAFLD: nonalcoholic fatty liver disease; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; OR: odds ratio; CI: confidence interval; HDL: high density lipoprotein; HOMA: homeostasis model assessment-estimated insulin resistance.